DSM Signs Development Contract with NKT

DSM Biologics today announced it has signed a contract with NKT Therapeutics, Inc. The deal covers the process development and cGMP manufacturing by DSM of their lead product iNKT mAb.

DSM Biologics, a business unit of DSM Pharmaceutical Products, has signed a contract with NKT Therapeutics, Inc. for the process development and cGMP manufacture of NKT’s lead product iNKT mAb. Financial terms of the contract were not disclosed.

NKT, based in Waltham, MA, is a biotechnology company that focuses on developing therapeutics based on immune cells called natural killer T (NKT) cells. NKT cells are a central part of the immune system. When exposed to microbial and viral pathogens, NKT cells secrete high levels of specific cytokines, which stimulate the immune system to eliminate pathogens.

Karen King, president of DSM Biologics, said, "We are d